Applied Genetic Technologies (AGTC) Reaches $3.75 After 4.00% Down Move; HEIDELBERGER DRUCKMA (HBGRF) Shorts Decreased By 4.35%

February 13, 2018 - By Vivian Park

The stock of Applied Genetic Technologies Corporation (NASDAQ:AGTC) is a huge mover today! The stock decreased 2.60% or $0.1 during the last trading session, reaching $3.75. About 64,569 shares traded. Applied Genetic Technologies Corporation (NASDAQ:AGTC) has declined 65.28% since February 13, 2017 and is downtrending. It has underperformed by 81.98% the S&P500.The move comes after 7 months negative chart setup for the $67.89 million company. It was reported on Feb, 13 by Barchart.com. We have $3.60 PT which if reached, will make NASDAQ:AGTC worth $2.72M less.

HEIDELBERGER DRUCKMA (OTCMKTS:HBGRF) had a decrease of 4.35% in short interest. HBGRF’s SI was 671,300 shares in February as released by FINRA. Its down 4.35% from 701,800 shares previously. It closed at $3.4 lastly. It is down 0.00% since February 13, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 10 analysts covering Applied Genetic (NASDAQ:AGTC), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Applied Genetic has $29 highest and $7 lowest target. $15.14’s average target is 303.73% above currents $3.75 stock price. Applied Genetic had 23 analyst reports since July 22, 2015 according to SRatingsIntel. The rating was initiated by Janney Capital on Friday, March 18 with “Buy”. The rating was maintained by H.C. Wainwright with “Buy” on Friday, June 9. The stock of Applied Genetic Technologies Corporation (NASDAQ:AGTC) has “Market Perform” rating given on Tuesday, September 13 by Wells Fargo. The firm earned “Hold” rating on Tuesday, September 13 by Cantor Fitzgerald. The stock has “Neutral” rating by Cantor Fitzgerald on Thursday, September 14. The stock of Applied Genetic Technologies Corporation (NASDAQ:AGTC) has “Buy” rating given on Tuesday, February 9 by Stifel Nicolaus. The firm has “Outperform” rating by BMO Capital Markets given on Thursday, September 14. The stock of Applied Genetic Technologies Corporation (NASDAQ:AGTC) earned “Outperform” rating by Wells Fargo on Friday, December 4. Wedbush maintained the stock with “Outperform” rating in Wednesday, November 9 report. The firm has “Outperform” rating given on Tuesday, September 13 by BMO Capital Markets.

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company has market cap of $67.89 million. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It currently has negative earnings. It has collaboration agreements with Biogen MA, Inc., 4D Molecular Therapeutics, Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation.

Investors sentiment decreased to 0.57 in 2017 Q3. Its down 0.19, from 0.76 in 2017Q2. It dropped, as 14 investors sold Applied Genetic Technologies Corporation shares while 23 reduced holdings. 10 funds opened positions while 11 raised stakes. 6.79 million shares or 17.89% less from 8.27 million shares in 2017Q2 were reported. Commercial Bank Of Montreal Can, a Ontario – Canada-based fund reported 58,102 shares. Bancshares Of America De accumulated 48,175 shares or 0% of the stock. Deutsche Financial Bank Ag stated it has 0% of its portfolio in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Price T Rowe Assocs Md accumulated 189,981 shares or 0% of the stock. Steinberg Global Asset invested in 113,123 shares. Massachusetts-based Geode Mngmt Limited Company has invested 0% in Applied Genetic Technologies Corporation (NASDAQ:AGTC). California Employees Retirement Sys stated it has 18,000 shares or 0% of all its holdings. Acadian Asset Management Ltd Liability Corp accumulated 0.01% or 692,197 shares. The Illinois-based Citadel Advsr Ltd Liability Company has invested 0% in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Altrinsic Advsrs Lc owns 229,000 shares. Ajo Ltd Partnership accumulated 0.01% or 468,986 shares. Walleye Trading Ltd, a Minnesota-based fund reported 11,677 shares. Nine Chapters Management Ltd has invested 0.25% in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Pennsylvania-based Nationwide Fund Advsr has invested 0% in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Mufg Americas, New York-based fund reported 360 shares.

Analysts await Applied Genetic Technologies Corporation (NASDAQ:AGTC) to report earnings on February, 14. They expect $-0.09 EPS, down 181.82% or $0.20 from last year’s $0.11 per share. After $-0.08 actual EPS reported by Applied Genetic Technologies Corporation for the previous quarter, Wall Street now forecasts 12.50% negative EPS growth.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>